{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:22:29Z","timestamp":1768638149727,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.02.030","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T01:02:35Z","timestamp":1586566955000},"page":"3902-3908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children"],"prefix":"10.1016","volume":"38","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aino","family":"Forsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"France","family":"Laudat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van Der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Hezareh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.02.030_b0005","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.02.030_b0010","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.030_b0015","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases, https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases; 2017 [accessed July 9, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.030_b0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","article-title":"Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies","volume":"15","author":"Booy","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.030_b0025","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC Annual epidemiological report for 2017, Stockholm: ECDC; 2019."},{"key":"10.1016\/j.vaccine.2020.02.030_b0030","doi-asserted-by":"crossref","first-page":"E454","DOI":"10.33321\/cdi.2016.40.50","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013\u20132015","volume":"40","author":"Martin","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2020.02.030_b0035","unstructured":"Menactra\u00ae (meningococcal (Groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine). Full Prescribing Information, Sanofi Pasteur Inc, Swiftwater, PA; 2016."},{"key":"10.1016\/j.vaccine.2020.02.030_b0040","unstructured":"Menveo\u00ae (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). Full Prescribing Information, Novartis, Sovicille, Italy; 2013."},{"key":"10.1016\/j.vaccine.2020.02.030_b0045","unstructured":"Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine). Summary of Product Characteristics, Pfizer Ltd, Sandwich, UK; 2019."},{"key":"10.1016\/j.vaccine.2020.02.030_b0050","unstructured":"Menactra (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection). Full Prescribing Information, Sanofi Pasteur Inc, Swiftwater, PA; 2018."},{"key":"10.1016\/j.vaccine.2020.02.030_b0055","unstructured":"Menveo\u00ae (Meningococcal (Groups A, C, Y, And W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). Full Prescribing Information, GlaxoSmithKline, Sovicille, Italy; 2018."},{"key":"10.1016\/j.vaccine.2020.02.030_b0060","unstructured":"Meningococcal group A, C, W135 and Y conjugate vaccine (Menveo). Summary of Product Characteristics, GSK Vaccines S.r.l., Siena, Italy; 2018."},{"key":"10.1016\/j.vaccine.2020.02.030_b0065","unstructured":"Nimenrix\u00ae: EPAR \u2013 product information. Summary of Product Characteristics; 2019."},{"key":"10.1016\/j.vaccine.2020.02.030_b0070","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.030_b0075","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.030_b0080","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/hv.20473","article-title":"Importance of circulating antibodies in protection against meningococcal disease","volume":"8","author":"Erlich","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.030_b0085","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2020.02.030_b0090","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.02.030_b0095","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.030_b0100","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.030_b0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trivac.2014.06.003","volume":"3","author":"Vesikari","year":"2014","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.vaccine.2020.02.030_b0110","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.vaccine.2018.02.013","article-title":"Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: a phase III, open-label, randomised study","volume":"36","author":"Cutland","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.030_b0115","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","volume":"15","author":"Findlow","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.030_b0120","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","article-title":"Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children","volume":"35","author":"Klein","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.030_b0125","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jpeds.2014.02.025","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"164","author":"Baxter","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2020.02.030_b0130","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.vaccine.2017.06.053","article-title":"Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: a randomized controlled trial","volume":"35","author":"van Ravenhorst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.030_b0135","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.vaccine.2019.01.008","article-title":"Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D)","volume":"37","author":"Robertson","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.030_b0140","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.030_b0145","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":"Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine","volume":"30","author":"MacNeil","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.030_b0150","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:27Z","timestamp":1759401807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20302279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":30,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20302279"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}